Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Eli Lilly & Co. Q3 2008 Earnings Conference Call Transcript
- Question-and-Answer SessionAbsolutely. [Operator Instructions]. And your first question is from the line of Tony Butler, Barclays Capital. Please go ahead. Anthony Butler - Barclays Capital Thanks very much. John, it would appear that Gemzar or Strattera and Evista may have actually peaked in sales, and I am curious if...
- Earnings calls 2008-10-23
Additional Resources
- Eli Lilly bets on Alimta. (Markets: Life Sciences).(Brief Article)(Statistical Data Included)
- ELI LILLY and Company reported positive Phase III trial data on Alimta pemetrexed in mesothelioma. Billed as a successor to its flagship oncology drug Gemzar gemcitabine, analysts project peak sales for Alimta at nearly $1 billion. ELI LILLY and Company reported positive...
- Research articles 2002-06-10
- Alimta, an Investigational Cancer Therapy, Featured in Presidential Symposium at 10th World Congress on Lung Cancer.
- VANCOUVER, BRITISH COLUMBIA, Aug 12, 2003 CCNMatthews via COMTEX Non-small cell lung cancer patients with recurrent disease treated with Eli Lilly and Company's pemetrexed (proposed brand name, AlimtaR) experienced similar survival but significantly fewer side effects than those receiving TaxotereR docetaxel. These Phase III...
- Research articles 2003-08-12
- Alfacell Corporation F3Q08 (Qtr End 04/30/2008) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Your first question comes from Stephen Dunn - Dawson James. Stephen Dunn - Dawson James Do you have your results of 122 patients? Do you have a hypothesis of the mechanism of actions for ONCONASE and why it would work...
- Earnings calls 2008-06-11
- Allos Therapeutics, Inc. Q2 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you, sir. Ladies and gentlemen, we will now begin the question-and-answer session. Operator instructions Our first question comes from the line of Lucy Lu with Citi group. Please go ahead. Lucy Lu – Citigroup Great. Thank you. Actually can you just please...
- Earnings calls 2008-09-08
- ELI LILLY AND COMPANY ACCELERATES CHINA EXPANSION
- AsiaInfo Services 12-20-2005 Eli Lilly and Company Accelerates China Expansion CHINA, Dec 20, 2005 SinoCast via COMTEX -- Eli Lilly and Company, which has not shaken off the Gemzar lawsuit, presented a new cancer drug Alimta in China recently AsiaInfo...
- Research articles 2005-12-20
- Lilly Profit Tops Estimates on Drug Sales, Taxes
- By Lewis Krauskopf NEW YORK (Reuters) - Eli Lilly and Co LLY posted third-quarter profit well above Wall Street expectations on Wednesday on strong performance of its major prescription drugs and lower taxes, sending shares up 1.9 percent. Sales of lung cancer treatment Alimta, anti-depressant Cymbalta, Humalog insulin and schizophrenia...
- News items 2009-10-21
- New Treatment Options Featured in NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines
- JENKINTOWN, Pa. -- The National Comprehensive Cancer Network NCCN, an alliance of nineteen of the world's leading cancer centers, announces that the NCCN Non-Small Cell Lung Cancer Guideline has recently been updated to broaden the options for treatment of advanced disease. NCCN's panel of oncology experts added pemetrexed (AlimtaR, Eli...
- Research articles 2005-03-01
- Eli Lilly & Co. Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionOur first question will come from the line Jim Kelly from Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you, and good morning. I have a question about the impact in volumes, just taking a look at the comparison from the last quarterly report, where...
- Earnings calls 2008-04-21
- EntreMed, Inc. Q2 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you. The call will now be opened for questions. Operator instructions Our first question is coming from Ren Benjamin with Rodman. Please go ahead. Ren Benjamin – Rodman & Renshaw Hi, good morning and thanks for taking the question. James Burns...
- Earnings calls 2008-09-23
- Stocks to Watch - LLY, INTL, VICL, GOOG.
- M2 PRESSWIRE-20 October 2006-SmallCapReview: Stocks to Watch - LLY, INTL, VICL, GOOGC1994-2006 M2 COMMUNICATIONS LTD RDATE:20102006 Eli Lilly (NYSE: LLY) Closed at $57.49. Has launched a major clinical trial evaluating ALIMTA pemetrexed for injection in extensive-stage small cell lung cancer SCLC,...
- Research articles 2006-10-20
- Lilly Q1: Price Rises, End of Zyprexa Woes Boost the Numbers
- With its costly Zyprexa settlements out of the way, Eli Lilly got back to business as usual: Raising drug prices. And it seems to have paid off. Lilly's Q1 revenue was $5 billion, up from $4.8 billion the year before (but down sequentially from mid-2008 when quarterly revenues touched $5.2...
- Blog posts 2009-04-20
- Idera Presents Preclinical Data at ASCO on Agonists to Toll-like Receptor 9 in Combination with Chemotherapeutic and Targeted Therapies in Lung Cancer Models; Results Emphasize Broad Spectrum Therapeutic Potential of Idera's Programs
- CAMBRIDGE, Mass. -- Idera Pharmaceuticals (AMEX: IDP) today announced that it had presented preclinical data for its TLR9 agonists in mouse lung cancer models at the American Society of Clinical Oncology ASCO Annual Meeting. These data demonstrate that in the preclinical studies conducted by Idera, Idera's TLR9 agonists enhanced the...
- Research articles 2006-06-05
- Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007.
- INDIANAPOLIS, May 23 /PRNewswire/ -- - 37 Thoracic Cancer Studies; 11 Breast Cancer Studies; 9 Targeted Agent Studies Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology ASCO in Chicago, Ill. from...
- Research articles 2007-05-23
- LILLY (ELI) & COMPANY - Potential Versatility of Alimta.
- ASCO Abstract #7517 For Release: June 2, 2007, 3:00 p.m. CDT Contact: Gregory L. Clarke, Lilly Neil Hochman, CPR Worldwide 317-276-5222 office 212-453-2067 office 317-554-7119 mobile 516-784-9089 mobile Email: gregory.clarke@lilly.com Email: n.hochman@cprworldwideusa.com ...
- Research articles 2007-06-04
- For Lilly, Challenges Remain
- Zacks.com submits: By Jason Napodano Eli Lilly and Company LLY Analyst Report turned in a solid year in 2007 and again in 2008. 2008 sales increased by 9% on strong sales of Cymbalta, Alimta, Byetta, Cialis and the Animal Health business. EPS grew even faster, at 13%, as...
- External links 2009-06-17
- Industry is on Board with Lung Cancer Maintenance, but are Docs?
- The FDA approved Eli Lilly’s chemotherapy drug Alimta pemetrexed as the first maintenance therapy for lung cancer, but as Lilly admits in its press release, the concept of maintenance therapy is not one lung cancer docs are familiar with. by Trista Morrison
- Blog posts 2009-07-10
- << Previous
- page 1 of 1
- Next >>
